ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Merck is launching a second collaboration with RNAi technology developer Alnylam Pharmaceuticals. Merck called its initial alliance with Alnylam, formed last September, one of the first big drug firm investments in a company developing RNAi, a recently discovered natural process by which cells inhibit the expression of disease-causing proteins. The new deal targets age-related macular degeneration and other ocular diseases. Merck's payments to Alnylam under this pact could total $19.5 million.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X